Abstract: A method of selecting a subject for administration of an anti-c-Met antibody, comprising (i) determining the presence or the amount of a ubiquitin peptidase, (ii) determining the presence or expression level of a ubiquitin peptidase coding gene, or (iii) measuring the activity of a ubiquitin peptidase, in a biological sample; as well as related methods.

Abstract: A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.

Abstract: A content program information search system and method is described. The system comprises a digital signal receiver for detecting and displaying a content signal and/or detailed content information for one or more search terms from a digital signal transmitted from a transmitter; and a server having a database for storing search terms inputted from external devices, the inputted search terms being stored by order of priority based for example on search frequency, such that the server extracts and transmits to the transmitter search terms from the first database, and the digital signal receiver displays according to the order of priority at least one search term transmitted from the transmitter. The viewer thus has search terms of high search frequency to enable the viewer to rapidly and easily search for information on a desired content program.

Abstract: Provided is a method for prevention or treatment of a cancer, comprising co-administering (a) an FGFR inhibitor and (b) an anti-c-Met antibody or antigen-binding fragment thereof to a subject in need thereof, wherein the anti-c-Met antibody or the antigen-binding fragment thereof specifically binds to an epitope comprising 5 or more contiguous amino acids within the SEMA domain of c-Met protein.

Abstract: Provided is a method of combination therapy for prevention or treatment of a cancer including or consisting essentially of co-administering sorafenib and an anti-c-Met antibody or an antigen-binding fragment thereof to a subject. The method of combination therapy can achieve an excellent synergistic effect and lower the effective dose of the anti-c-Met antibody, thereby enabling a more effective cancer treatment.

Abstract: A method for inhibiting angiogenesis and treating angiogenesis related diseases comprising administering an anti-c-Met antibody or an antigen-binding fragment thereof, and an anti-Ang-2 antibody or an antigen-binding fragment thereof, in combination simultaneously or sequentially; as well as related compositions and methods.

Abstract: A method of combination therapy for prevention and/or treatment of c-Met- and/or EGFR-induced diseases including co-administering a pharmaceutically effective amount of an EGFR antagonist and a pharmaceutically effective amount of an anti-c-Met antibody to a subject in need thereof is provided.

Abstract: There are provided a composition for determining the efficacy of a c-Met antibody including marker genes and a method for determining the efficacy of a c-Met antibody using the marker genes.

Abstract: Provided is a humanized and affinity-matured anti-c-Met antibody, a pharmaceutical composition including the antibody, and a method of preventing and/or treating c-Met-related disease using the antibody.

Abstract: There are provided a fusion protein formed by coupling of anti-c-Met antibody and VEGF-binding fragment, a bispecific antibody comprising the fusion protein, a polynucleotide encoding the fusion protein, a transformant comprising the polynucleotide, a pharmaceutical composition comprising the bispecific antibody as an active ingredient, and a method for preparing the bispecific antibody which is targeted at c-Met and VEGF at the same time, with improved anticancer and anti-angiogenesis effects, comprising coupling an anti-c-Met antibody with a VEGF-binding fragment.

Abstract: A method of preventing and/or treating a cancer comprising co-administering a p53 activator and a c-Met inhibitor to a patient in need thereof.

Abstract: Biomarkers for screening drugs reducing side effects of anti-c-Met antibodies and a method of screening using the biomarkers, and more particularly, biomarkers commonly enhancing or reducing gene expression and a method of screening anti-c-Met antibodies having reduced side effects using the biomarkers or a method of screening drugs that reduce side effects of anti-c-Met antibodies.

Abstract: An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided.

Abstract: A method of identifying a cell sample or a subject suitable for treatment with an anti-c-Met antibody or antigen binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining a Cbl concentration, a Cbl mutation, and/or a mutation of a site of c-Met for interaction with Cbl in a cell sample from a subject, as well as related compositions and methods.

Abstract: A method of identifying a cell sample or subject suitable for treatment with an anti-c-Met antibody or antigen-binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining the presence of LRIG1 in a cell sample from the subject, as well as related methods and compositions.

Abstract: Provided is a method of combination therapy for prevention or treatment of c-Met-induced or angiogenesis factor-induced diseases including co-administering an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof to a patient.

Abstract: The present invention relates to a lancet device that can solve the problem of falling or losing a cover when mounting or separating a lancet and reduce the pain that accompanies blood-taking. A lancet device according to an exemplary embodiment of the present invention includes: a lancet holder having a lancet seat to mount a lancet at one end; an operating mechanism disposed at the other end of the lancet holder and loading and releasing the lancet holder along a predetermined path; and an a housing receiving the operating mechanism and having one end coupled to the lancet holder, and further includes a cover that covers the housing so that the lancet holder is received in the housing, is at least partially connected with the housing in order not to separate from the housing in use, and has protrusions on the front part.

Abstract: A releasing structure for a lancing device according to an exemplary embodiment of the present invention may include: a lancet body with a lancet at the front; a lancet holder mounted with the lancet body with the lancet at the front; a stem disposed behind the lancet holder and moving the lancet holder forward/backward; a rotary housing pushing/pulling the stem while turning forward at a predetermined angle about a rotational axis defined in the movement direction of the lancet; a torsion spring storing torque for turning the rotary housing forward at a predetermined angle; and a loading handle transmitting torque to the torsion spring while turning forward at a predetermined angle.

Abstract: The present invention provides a lancet holder that can smoothly and accurately hold all of lancets with different cross-sections and diameters and can keep them vertical, and a lancet device including the lancet holder. To this end, a lancet holder according to an exemplary embodiment of the present invention includes a holder body having a lancet seat at one end to mount a lancet and receiving the lancet and elastic fixing portions arranged in pairs to face each other on the inner side of the holder body so that the lancet received in the holder body is vertically held, and elastically fixing the lancet.

Abstract: A lancet-separable lancet device according to an exemplary embodiment of the present invention includes: a lancet holder having a lancet seat to mount a lancet at one end and a separation hole at the other end; an operating mechanism disposed at the other end of the lancet holder so that the lancet holder is loaded and released by traveling along a predetermined path; a housing receiving the operating mechanism and having one end coupled to the lancet holder; an operation switch connected to the operating mechanism and operating the operating mechanism by pressing it; a cover covering one end of the housing and having a through-hole at the center through which a lancet needle of the lancet instantaneously protrudes; and a lancet separation mechanism disposed at the other side of the lancet holder and separating the lancet from the lancet holder by being inserted into the separation hole of the lancet holder.